Retatrutide, also known as LY3437943, is an investigational once-weekly injectable medication developed by Eli Lilly
Together this phenomenon is collectively referred to as the gray market. This gray market is not subject to the quality control regulations that govern the pharmaceutical industry, and testing conducted on a range of peptides including MOTS-c, BPC-157, TB-500, and CJC-1295 by The New Yorker in April showed that many were impure or contained less than the advertised dose
Key Takeaways Diabetes can cause excessive sweating through nerve damage (autonomic neuropathy), medication side effects, or low blood sugar
BPC-157 and TB-500 are often studied together due to their complementary research profiles
It's prudent to really weigh a mix of technicals, fundamentals, and relative value
Larsen WJ